Optimizing development of anti-TNFα biosimilars based on 10 years’ experience
Routine regulatory requirements for large comparative efficacy trials (CETs) to support marketing approval of monoclonal antibody (mAb) biosimilars have been the focus of extensive debate in the last few years. This review examines the mounting evidence, accumulated over the past decade, focusing on...
Salvato in:
| Autore principale: | |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Open Exploration Publishing Inc.
2025-02-01
|
| Serie: | Exploration of Musculoskeletal Diseases |
| Soggetti: | |
| Accesso online: | https://www.explorationpub.com/uploads/Article/A100782/100782.pdf |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|